ZL-6201 / ZAI Lab - LARVOL DELTA

Expected Clinical Developments and Data Readouts:…ZL-6201 (LRRC15 ADC) (Businesswire) - "Zai Lab to submit an Investigational New Drug application to the FDA for a global Phase 1 study for patients with sarcoma and potentially other LRRC15-positive solid tumors in the fourth quarter of 2025."

IND • Sarcoma

Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025 (Businesswire) - "Findings to be presented at AACR 2025 on Tuesday, April 29, demonstrate that ZL-6201 efficiently internalizes within and kills tumor cells, while also exhibiting a strong bystander killing effect in the tumor microenvironment where the target is often expressed. In multiple in vitro and in vivo pre-clinical studies, treatment with ZL-6201 effectively suppressed the growth of established tumors. Based on these findings, Zai Lab plans to initiate Investigational New Drug (IND)-enabling studies of ZL-6201 as a potential treatment for patients with sarcoma and other LRRC15-positive solid tumors, such as breast cancer and other malignancies, in 2025....Findings from preclinical studies to be presented Monday, April 28, at AACR 2025 suggest that ZL-1222, through precisely tailored IL-12 activity and PD-1 targeting, demonstrate potent anti-tumor activity in both anti-PD-1 sensitive and resistant tumor models, with improved systemic safety."

Preclinical • Breast Cancer • Hematological Malignancies • Sarcoma • Solid Tumor

Discovery and characterization of a novel LRRC15-targeting antibody drug conjugate (ADC) for the treatment of solid tumors (AACR 2025) - "In a human chondrosarcoma SA4109 PDX model, a significantly higher concentration of payload and ADC were detected in the tumors compared to mouse serum, indicating targeted delivery of the ADC. Collectively, these findings support advancing ZL-6201 into IND-enabling studies as a potential treatment for patients with sarcoma and other LRRC15-positive solid tumors."

Brain Cancer • CNS Tumor • Glioblastoma • Melanoma • Oncology • Sarcoma • Solid Tumor • CAFs • LRRC1

Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting (Businesswire) - "Poster presentation will highlight the potential of ZL-6201 as an innovative antibody-drug conjugate (ADC) for the treatment of sarcoma and other leucine-rich repeat-containing protein 15 (LRRC15)-positive solid tumors. Late-breaking poster presentation will summarize data from preclinical evaluation of ZL-1222, a promising next-generation interleukin-12 (IL-12) immunocytokine therapy for the treatment of various cancers."

Late-breaking abstract • Preclinical • Sarcoma • Solid Tumor

Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate (Businesswire) - "Zai Lab Limited...announced a new strategic collaboration and worldwide license agreement with MediLink Therapeutics...to use MediLink’s TMALIN antibody-drug conjugate (ADC) platform for the development of a novel LRRC15 ADC, ZL-6201, consisting of an antibody discovered by Zai Lab. Through this collaboration, Zai Lab further expands its global oncology pipeline with another potential first-in-class ADC targeting multiple solid tumors and addressing significant unmet medical needs. ZL-6201 has demonstrated encouraging preclinical data with an IND expected to be filed in 2025."

IND • Licensing / partnership • Solid Tumor